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Regulation of G protein-coupled 
receptor signaling by nitric oxide
G protein-coupled receptors (GPCRs) constitute the 
largest known family of cell-surface receptors and are 
fundamentally involved in mammalian physiology. β-
adrenergic receptors (β-ARs) and AT1 angiotensin receptors 
are prototypical GPCRs, both playing a critical role in the 
regulation of cardiovascular, pulmonary, renal, and other 
functions. Ligand signaling by GPCRs is quickly followed 
by receptor desensitization. But, in addition, loss of receptor 
responsiveness may contribute to disease. For example, loss of 
β-AR responsivity is thought to be linked to both heart failure 
and asthma. Th e GPCR kinases (GRKs) curtail G protein 
signaling by phosphorylating agonist-occupied receptors 
and promoting their desensitization, internalization, and 
downregulation.
Nitric oxide (NO) and low-molecular weight S-nitrosothiols 
(SNOs) regulate a diverse array of signal transduction pathways, 
acting in signifi cant part through the covalent modifi cation 
(S-nitrosylation) of cysteine residues that are found at active 
or allosteric sites of proteins. Recent evidence indicates 
that signaling through GPCRs might also be regulated by 
S-nitrosylation. For example, exposure of cells and tissues 
to nitrosylating agents inhibits or potentiates the signaling 
of multiple GPCRs, and the cysteine residues that confer 
NO responsivity have been identifi ed in the β2-AR and AT1 
angiotensin receptors. Interestingly, diminished responsiveness 
to β2-AR agonists as assessed by vasodilation can be reversed by 
administration of SNOs, and mice with a genetic alteration that 
impairs breakdown of SNOs are protected from tachyphylaxis. 
In a recent communication, Whalen et al. investigated the 
molecular mechanism(s) by which NO or SNOs preserve 
β-AR function. Th ey found in mice that SNOs increased 
β-AR expression and prevented agonist-stimulated receptor 
downregulation. In cells, SNOs decreased GRK2-mediated 
β-AR phosphorylation and subsequent recruitment of β-
arrestin to the receptor, resulting in attenuation of receptor 
desensitization and internalization. In both cells and tissues, 
GRK2 (Figure) was S-nitrosylated by SNOs as well as by NO 
synthases, and GRK2 S-nitrosylation increased aft er stimulation 
of multiple GPCRs with agonists. Th e Cys340 of GRK2 was 
identifi ed as a principal locus of inhibition by S-nitrosylation. 
Th ese elegant studies reveal a central molecular mechanism 
through which GPCR signaling is regulated. (Cell 2007; 129: 
511–522)
Juan Oliver
Mesenchymal stem cells prevent 
renal failure but maldifferentiate 
into glomerular adipocytes
Glomerulonephritis is a major cause of renal failure. In a new 
study, Kunter et al. sought to determine whether intrarenal 
injection of rat mesenchymal stem cells (MSCs) can preserve 
renal function. At day 10, fl uorescently labeled rat MSCs 
localized to more than 70% of glomeruli, ameliorated acute 
renal failure, and reduced glomerular adhesions. Fift y days 
later, proteinuria had progressed to 40 ± 25 mg per day in 
controls but stayed low in MSC-treated rats (13 ± 4 mg per 
day; P < 0.01). At day 60, renal function was better in the MSC 
group than in medium controls. Kidneys of the MSC group 
on day 60 contained 11% more glomeruli per 1 mm2 section 
of cortex but also signifi cantly more collagen types I, III, and 
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Morphology of adipocytes in MSC-treated Lewis rats with anti-Thy1.1 
nephritis on day 60.
Activation loops of GRK2 and cyclic AMP-dependent protein kinase 
(PKA), a prototypic AGC kinase.
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IV and α-smooth muscle actin as compared with controls 
(Figure). Approximately 20% of the glomeruli of MSC-
treated rats contained single, or clusters of, large adipocytes 
with pronounced surrounding fi brosis. Adipocytes exhibited 
fl uorescence in their cytoplasm and/or intracellular lipid 
droplets. Lipid composition in these adipocytes in vivo mirrored 
that of MSCs that underwent adipogenic diff erentiation in 
vitro. Th e early benefi cial eff ect of MSCs of preserving damaged 
glomeruli and maintaining renal function was off set by a 
long-term partial maldiff erentiation of intraglomerular MSCs 
into adipocytes, accompanied by glomerular sclerosis. Th ese 
data suggest that MSC treatment can be a valuable therapeutic 
approach only if adipogenic maldiff erentiation is prevented. 
(J Am Soc Nephrol 2007; 18: 1754–1764)
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Diagnostic thresholds for 
ambulatory blood pressure
Blood pressure measurement is the basis for the diagnosis 
and treatment of hypertension. Conventional blood pressure 
measurement by auscultation of the Korotkoff  sounds is fraught 
with potential sources of error. Ambulatory monitoring allows 
registration of the blood pressure throughout the entire day in 
subjects engaged in their usual activities. Ambulatory blood 
pressure recordings have high reproducibility, are not subject to 
digit preference, and avoid the transient rise of a patient’s blood 
pressure in response to a medical environment, the so-called 
white-coat eff ect.
Although blood pressure is continuously distributed, 
clinicians need a diagnostic frame of reference to interpret 
ambulatory blood pressure values and to classify patients. 
Current guidelines propose operational thresholds for the 
ambulatory blood pressure, but these limits are not outcome 
driven, relying largely on the distribution of the ambulatory 
blood pressure in normotensive reference populations or on 
the regression of ambulatory on conventional blood pressure. 
Kikuya et al. thus constructed an international population-
based database with the objective of determining diagnostic 
thresholds for ambulatory blood pressure monitoring in terms 
of cardiovascular outcome.
Th ey performed 24-hour ambulatory blood pressure 
monitoring in 5682 participants (mean age 59.0 years; 43.3% 
women) enrolled in several prospective population studies. In 
multivariate analyses, they determined pressure thresholds, 
which yielded 10-year cardiovascular risks similar to those 
associated with optimal (120/80 mm Hg), normal (130/85 mm 
Hg), and high (140/90 mm Hg) blood pressure on offi  ce 
measurement. During 9.7 years (median), 814 cardiovascular 
events occurred, including 377 strokes and 435 cardiac events. 
Rounded thresholds for optimal ambulatory blood pressure 
amounted to 115/75 mm Hg for 24 hours, 120/80 mm Hg for 
daytime, and 100/65 mm Hg for nighttime. Rounded thresholds 
for normal ambulatory blood pressure were 125/75, 130/85, 
and 110/70 mm Hg, respectively, and those for ambulatory 
hypertension were 130/80, 140/85, and 120/70 mm Hg. Th ese 
data, obtained from a large international database from a 
random sample of the general population, are of great interest 
and give calculated thresholds generally lower than previously 
estimated. A randomized therapeutic trial is now needed to test 
whether ambulatory blood pressure is superior to traditional 
blood pressure measurements used in the clinic. (Circulation 
2007; 115: 2145–2152)
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Acute and chronic complications of 
type 2 diabetes mellitus in children 
and adolescents
With the increase in prevalence of type 2 diabetes mellitus in 
adolescents, clinicians anticipate a rise in incidence of secondary 
comorbidities, including hypertension, hyperlipidemia, 
nephropathy, and retinopathy. Findings of studies in young 
adults have suggested that the development and progression of 
clinical complications might be especially rapid when type 2 
diabetes develops early in life, raising the possibility of a serious 
public-health challenge in the next few decades. Furthermore, 
adolescents with type 2 diabetes show poor adherence to medical 
care and treatment and, therefore, could be at especially high risk 
for development of early complications. To date, reports of the 
epidemiology and natural history of secondary complications 
specifi cally in adolescents with type 2 diabetes have been scarce. 
A new review by Pinhas-Hamiel and Zeitler shows evidence of 
more aggressive development of clinical complications — 
particularly microalbuminuria and risk of myocardial infarction 
— in adults diagnosed with type 2 diabetes between the ages 
of 18 and 44 years than in those identifi ed aft er 45 years of age. 
Th eir detailed analysis of the literature found evidence of acute 
complications, including diabetic ketoacidosis, hyperglycemic 
hyperosmolar state, and malignant hyperthermia-like syndrome 
with rhabdomyolysis. Chronic complications identifi ed in their 
analysis included hypertension, microalbuminuria, background 
retinopathy, dyslipidemia, non-alcoholic fatty liver disease, 
cardiovascular and atherosclerotic complications, neuropathy, 
psychiatric disorders, health-related quality of life, and 
gestational diabetes.
Th e authors conclude that changes to substantial morbidity 
and mortality have been reported in children and adolescents 
with type 2 diabetes. Th ey highlight that microvascular 
complications can be present at the time of diagnosis and have a 
higher rate of progression in young people with type 2 diabetes 
than in those with type 1 diabetes. Th ese fi ndings, although still 
limited, suggest the urgent need to develop awareness and early 
management of type 2 diabetes and associated abnormalities. 
In addition, long-term studies are needed to establish the value 
of early initiation of adjunctive treatments. (Lancet 2007; 369: 
1823–1831)
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